1. Involvement of receptor-bound prorenin in development of nephropathy in diabetic db/db mice 
Atsuhiro Ichihara, MD, PhD, FAHA, Mariyo Sakoda, MD, Asako Kurauchi-Mito, MD, Akira Nishiyama, MD, PhD, FAHA, Hiroshi Itoh, MD, PhD 
Journal of the American Society of Hypertension 
Volume 2, Issue 5, Pages (September 2008)
DOI: /j.jash
Copyright © 2008 American Society of Hypertension Terms and Conditions

2. Figure 1
Preparation of the HRP corresponding to the “handle region” of the prosegment of mouse Ren1-prorenin. (A) Amino acid sequences of the prosegment of the mouse Ren1-prorenin and HRP. (B) Mass of prepared mouse HRP. (C) Mouse HRP (1 μM) binds to anti-mouse-HRP antibody (3 nM) but not to anti-mouse-renin antibody (3 nM). (D) Interference of the recombinant mouse Ren1-prorenin (10 nM) binding to anti-mouse-HRP antibody (3 nM) by mouse HRP (1 μM), but not by NH2-MTRLSAE-COOH (positions 30–36 of prorenin prosegment; 1 μM). HRP, handle region peptide.
Journal of the American Society of Hypertension 2008 2, DOI: ( /j.jash )
Copyright © 2008 American Society of Hypertension Terms and Conditions

3. Figure 2
Kidney sections stained using the periodic acid–Schiff method in db/db mice treated with the HRP or the control peptide and db/m mice treated with HRP or the control peptide at 16 weeks of age. Scale bars: 25 μm. The glomerulosclerosis index was significantly higher in the db/db mice than in the db/m mice, but the elevation was significantly inhibited by HRP treatment. HRP, handle region peptide. *P < .05 for db/db mice vs. db/m mice. †P < .05 for HRP treatment vs. control peptide treatment.
Journal of the American Society of Hypertension 2008 2, DOI: ( /j.jash )
Copyright © 2008 American Society of Hypertension Terms and Conditions

4. Figure 3
Immunohistochemical stainings with an antibody to the active site of renin in db/db mice treated with the HRP or the control peptide and db/m mice treated with the HRP or the control peptide at 16 weeks of age. Scale bars: 25 μm. Analyses of active-site-of-renin-positive cells showed an elevation in immunoreactivity for the active site of renin in the juxtaglomerular area of db/db mice; this elevation was reduced by treatment with HRP. Immunostaining for the active site of renin was weak in the kidneys of db/m mice and db/m + HRP mice. HRP, handle region peptide. *P < .05 for db/db mice vs. db/m mice. †P < .05 for HRP treatment vs. vehicle treatment.
Journal of the American Society of Hypertension 2008 2, DOI: ( /j.jash )
Copyright © 2008 American Society of Hypertension Terms and Conditions

5. Figure 4
Kidney prorenin mRNA, the total renin (renin plus prorenin) content, and (pro)renin receptor mRNA levels in db/m mice treated with the HRP or the control peptide and db/db mice treated with HRP or the control peptide at 16 weeks of age (n = 8 in each). The graphs show an elevation in the kidney levels of prorenin mRNA and the total renin content in db/db mice; HRP treatment had no effect on these levels. HRP, handle region peptide. *P < .05 vs. db/m mice.
Journal of the American Society of Hypertension 2008 2, DOI: ( /j.jash )
Copyright © 2008 American Society of Hypertension Terms and Conditions

6. Figure 5
Kidney Ang I and II levels in db/m mice treated with the HRP or the control peptide and db/db mice treated with HRP or the vehicle at 16 weeks of age (n = 8 in each). The graphs show elevations in kidney Ang I and II levels in db/db mice, and HRP significantly inhibited the elevations in kidney Ang I and II levels in db/db mice. Ang, angiotensin; HRP, handle region peptide. *P < .05 for db/db mice vs. db/m mice. †P < .05 for HRP treatment vs. vehicle treatment.
Journal of the American Society of Hypertension 2008 2, DOI: ( /j.jash )
Copyright © 2008 American Society of Hypertension Terms and Conditions

7. Figure 6
Kidney mRNA levels of angiotensinogen and ACE in db/m mice treated with the HRP or the control peptide and db/db mice treated with HRP or the control peptide at 16 weeks of age (n = 8 in each). The graph shows an elevation in the kidney angiotensinogen mRNA level and a decrease in the kidney ACE level in db/db mice; HRP had no effect on these levels. ACE, angiotensin-converting enzyme; HRP, handle region peptide. *P < .05 vs. db/m mice.
Journal of the American Society of Hypertension 2008 2, DOI: ( /j.jash )
Copyright © 2008 American Society of Hypertension Terms and Conditions

8. Figure 7
Immunohistochemistry of phospho-ERK 1/2 in db/db mice treated with HRP or the control peptide and db/m mice treated with HRP or the control peptide at 16 weeks of age. Scale bars: 25 μm. The percentage of phosphor-ERK–positive glomeruli in the cross-section was significantly higher in the glomeruli of the kidneys from db/db mice. HRP treatment significantly inhibited the elevated immunoreactivity of phospho-ERK in the db/db mice. ERK, extracellular-signal–related protein kinase; HRP, handle region peptide; *P < .05 for db/db mice vs. db/m mice. †P < .05 for HRP treatment vs. the control peptide.
Journal of the American Society of Hypertension 2008 2, DOI: ( /j.jash )
Copyright © 2008 American Society of Hypertension Terms and Conditions